Not today, Mr. Speaker.
What is very peculiar is that we already have the most pro generic pharmaceutical policy in the developed countries. We have permitted exceptions which allow generic drugs to get to the market quicker than would otherwise be the case. These exceptions are not generally offered in other developed countries.
We have devised a system which we think achieves the correct balance between giving effective 20 year protection, as is our obligation under international treaty, and enabling generic drugs to enter the market as soon as the 20 years has ended. That is the appropriate balance.